AtriCure Q3 revenue $98.3M (+18% YoY); positive adjusted EBITDA $4.7M

AtriCure, Inc.

2023-Q3 EPS reported -$0.45 revenue$292,702,000

Worldwide revenue $98.3M, up 18.1% YoY; U.S. $81.7M (+17.1%), International $16.6M (+23.2%).
Net loss of $9.1M, improved $3.2M YoY; GAAP EPS loss $0.20, same as adjusted.
Positive adjusted EBITDA of $4.7M vs. negative $0.7M in Q3 2022, an improvement of $5.4M.
FY2023 revenue guidance $394M-$396M (19-20% growth); adjusted EBITDA $18M-$20M.
Gross margin 75.2%, up 110 bps YoY, driven by operational efficiencies and production leverage.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AtriCure, Inc. reported third quarter ended September 30, 2023 results: revenue $98.3 million, net income Net loss of $9.1 million, EPS $0.20.

Period: third quarter ended September 30, 2023
Revenue: $98.3 million
Net income: Net loss of $9.1 million
EPS: $0.20
Result: reported results

Exact text from the filing

Worldwide revenue of $98.3 million – an increase of 18.1% year over year • U.S. revenue of $81.7 million – an increase of 17.1% year over year • International revenue of $16.6 million – an increase of 23.2% year over year • Net loss of $9.1 million – an improvement of $3.2 million year over year

View on SEC.gov

Browse all earnings releases →

AtriCure, Inc. filing history →

Source: SEC EDGAR

accession 0001323885-23-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.